30 results on '"Goyal L"'
Search Results
2. Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.
- Author
-
Budhu A, Pehrsson EC, He A, Goyal L, Kelley RK, Dang H, Xie C, Monge C, Tandon M, Ma L, Revsine M, Kuhlman L, Zhang K, Baiev I, Lamm R, Patel K, Kleiner DE, Hewitt SM, Tran B, Shetty J, Wu X, Zhao Y, Shen TW, Choudhari S, Kriga Y, Ylaya K, Warner AC, Edmondson EF, Forgues M, Greten TF, and Wang XW
- Subjects
- Humans, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Retrospective Studies, Immunotherapy, Genomics, Carcinoma, Hepatocellular therapy, Liver Neoplasms therapy
- Abstract
Primary liver cancer is a rising cause of cancer deaths in the US. Although immunotherapy with immune checkpoint inhibitors induces a potent response in a subset of patients, response rates vary among individuals. Predicting which patients will respond to immune checkpoint inhibitors is of great interest in the field. In a retrospective arm of the National Cancer Institute Cancers of the Liver: Accelerating Research of Immunotherapy by a Transdisciplinary Network (NCI-CLARITY) study, we use archived formalin-fixed, paraffin-embedded samples to profile the transcriptome and genomic alterations among 86 hepatocellular carcinoma and cholangiocarcinoma patients prior to and following immune checkpoint inhibitor treatment. Using supervised and unsupervised approaches, we identify stable molecular subtypes linked to overall survival and distinguished by two axes of aggressive tumor biology and microenvironmental features. Moreover, molecular responses to immune checkpoint inhibitor treatment differ between subtypes. Thus, patients with heterogeneous liver cancer may be stratified by molecular status indicative of treatment response to immune checkpoint inhibitors., Competing Interests: Declaration of interests The authors declare no competing interests., (Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
3. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
- Author
-
Pal Chaudhary S, Reyes S, Chase ML, Govindan A, Zhao L, Luther J, Bhan I, Bethea E, Franses JW, Paige Walsh E, Anne Dageford L, Kimura S, Elias N, Yeh H, Markman J, Bozorgzadeh A, Tanabe K, Ferrone C, Zhu AX, Andersson K, Thiim M, Antonio Catalano O, Kambadakone A, Vagefi PA, Qadan M, Pratt D, Hashemi N, Corey KE, Misdraji J, Goyal L, and Clark JW
- Subjects
- Humans, Female, Retrospective Studies, Liver Cirrhosis pathology, Carcinoma, Hepatocellular pathology, Non-alcoholic Fatty Liver Disease complications, Non-alcoholic Fatty Liver Disease surgery, Liver Neoplasms pathology
- Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are the leading causes of hepatocellular carcinoma (HCC) worldwide. Limited data exist on surgical outcomes for NAFLD/NASH-related HCC compared with other HCC etiologies. We evaluated differences in clinicopathological characteristics and outcomes of patients undergoing surgical resection for NAFLD/NASH-associated HCC compared with other HCC etiologies., Methods: Demographic, clinicopathological features, and survival outcomes of patients with surgically resected HCC were collected. NAFLD activity score (NAS) and fibrosis score were assessed by focused pathologic review in a subset of patients., Results: Among 492 patients screened, 260 met eligibility (NAFLD/NASH [n = 110], and other etiologies [n = 150]). Median age at diagnosis was higher in the NAFLD/NASH HCC cohort compared with the other etiologies cohort (66.7 vs. 63.4 years, respectively, P = .005), with an increased percentage of female patients (36% vs. 18%, P = .001). NAFLD/NASH-related tumors were more commonly >5 cm (66.0% vs. 45%, P = .001). There were no significant differences in rates of lymphovascular or perineural invasion, histologic grade, or serum AFP levels. The NAFLD/NASH cohort had lower rates of background liver fibrosis, lower AST and ALT levels, and higher platelet counts (P < .01 for all). Median overall survival (OS) was numerically shorter in NAFLD/NASH vs other etiology groups, however, not statistically significant., Conclusions: Patients with NAFLD/NASH-related HCC more commonly lacked liver fibrosis and presented with larger HCCs compared with patients with HCC from other etiologies. No differences were seen in rates of other high-risk features or survival. With the caveat of sample size and retrospective analysis, this supports a similar decision-making approach regarding surgical resection for NAFLD/NASH and other etiology-related HCCs., (© The Author(s) 2023. Published by Oxford University Press.)
- Published
- 2023
- Full Text
- View/download PDF
4. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
- Author
-
Finn RS, Yau T, Hsu CH, De Toni EN, Goyal L, Galle PR, Qin S, Rao S, Sun F, Wang C, Widau RC, and Zhu AX
- Subjects
- Humans, Sorafenib therapeutic use, alpha-Fetoproteins, Europe, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy
- Abstract
Background: Ramucirumab is indicated for patients with advanced hepatocellular carcinoma (HCC) and α-fetoprotein (AFP) ≥400 ng/mL following sorafenib. Here, we prospectively studied ramucirumab following non-sorafenib systemic therapies., Materials and Methods: This open-label, non-comparative cohort of REACH-2 enrolled patients with advanced HCC, Child-Pugh class-A liver disease, and AFP ≥400 ng/mL who had received 1-2 lines of therapy, excluding sorafenib or chemotherapy. Ramucirumab was administered 8 mg/kg intravenously Q2W. The primary endpoint was safety. Secondary endpoints were overall survival, progression-free survival, objective response rate (RECIST v1.1), time to progression, pharmacokinetics, and patient-reported outcomes. Final analysis occurred after all enrolled patients completed ≥3 treatment cycles or discontinued treatment., Results: Between April 27, 2018, and March 29, 2021, 47 patients were treated at 21 investigative sites in Asia, Europe, and USA. The most frequently reported grade ≥3 adverse events, regardless of causality, were hypertension (11%), proteinuria (6%), hyponatremia (6%), and AST increased (6%). Two patients died from adverse events (myocardial infarction and upper gastrointestinal hemorrhage), deemed related to treatment. Median progression-free survival, time to progression, and overall survival were 1.7 months, 2.8 months, and 8.7 months, respectively. The objective response rate was 10.6% with a median duration response of 8.3 months. Median time to deterioration in FHSI-8 total score was 4.4 months., Conclusion: Ramucirumab demonstrated consistent and meaningful clinical activity with no new safety signals following non-sorafenib therapies in patients with advanced HCC and AFP ≥400 ng/mL. This represents one of the first sequencing studies for patients with advanced HCC not treated with sorafenib., (© The Author(s) 2022. Published by Oxford University Press.)
- Published
- 2022
- Full Text
- View/download PDF
5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
- Author
-
Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, and Melero I
- Subjects
- Carcinoma, Hepatocellular pathology, Guidelines as Topic, Humans, Liver Neoplasms pathology, Carcinoma, Hepatocellular drug therapy, Immunotherapy methods, Liver Neoplasms drug therapy
- Abstract
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunotherapy has demonstrated safety and efficacy in later lines of therapy as well, and ongoing trials are investigating novel combinations of ICIs and TKIs, in addition to interventions earlier in the course of disease or in combination with liver-directed therapies. Because HCC usually develops against a background of cirrhosis, immunotherapy for liver tumors is complex and oncologists need to account for both immunological and hepatological considerations when developing a treatment plan for their patients. To provide guidance to the oncology community on important concerns for the immunotherapeutic care of HCC, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for HCC, including diagnosis and staging, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with HCC., Competing Interests: Competing interests: GKA-A—Consulting fees: Agios, AstraZeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, Debio, Eisai, Eli Lilly, Flatiron, Genentech, Gilead, Incyte, Ipsen, LAM, Merck, MINA, QED, Redhill; Contracted research: Agios, AstraZeneca, Bayer, Berry Genomics, Bristol-Myers Squibb, Casi, Exelixis, Genoscience, Incyte, Polaris, Puma, QED, Sillajen; IP rights: ARTICLES AND METHODS FOR PREVENTING AND TREATING DERMATOLOGIC ADVERSE EVENTS, identified by International Patent Application No. PCT/US2014/031545 filed on March 24, 2014, and priority application Serial No.: 61/804,907 filed on March 25, 2013; Partner consulting fees: Celgene, CytomX, Loxo, Merck, Silenseed, Sobi, Twoxar; Partner contracted research: ActaBiologica, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Halozyme, Mabvax, Roche, Silenseed. A-LC—Consulting fees: AstraZeneca, Bristol-Myers Squibb, Eisai, Merck Serono, Novartis, Ono Pharmaceutical, Exelixis, Nucleix, IPSEN Innovation, Bayer Healthcare, Merck Sharp Dohme. AGD—Consulting fees: AstraZeneca. ABE-K—Consulting fees: Bayer, Bristol-Myers Squibb, EISAI, Merck, Exelixis, Roche/Genentech, Agenus, Gilead, AstraZeneca, Target Pharma Solutions; Contracted research: AstraZeneca, Astex; Non-CME services: Bayer, Bristol-Myers Squibb, EISAI, Merck, Exelixis, Roche/Genentech. RSF—Consulting fees: AstraZeneca, Bayer, Eisai, CStone, Bristol-Myers Squibb, Eli Lilly, Exilexis, Merck, Pfizer, Roche/ Genentech; Contracted research: UCLA, Eisai, Merck, Bristol-Myers Squibb, Roche/ Genentech, Pfizer, Eli Lilly. PRG—Consulting fees: Bayer, Bristol-Myers Squibb, AstraZeneca, Sirtex, MSD, Eisai, Ipsen, Roche, Lilly, Adaptimmune; Contracted research: Bayer. TFG—Contracted research: Astra Zeneca, Bristol-Myers Squibb, Merck, Sillajen, Vascular Biogenics,. LG—Consulting fees: Agios, Debiopharm, Taiho, Alentis, Incyte, Klus, Pieris, QED, SIRTEX, AstraZeneca, H3Biomedicine. ARH—Consulting fees: Merck, Bayer, Bristol-Myers Squibb, AstraZeneca; Contracted research: Merck, Genentech; Non-CME services: Eisai, Bristol-Myers Squibb, Exelixis. AOK—Consulting fees: Bristol-Myers Squibb, Roche/Genentech, Exelixis, Eisai; Contracted research: Bristol-Myers Squibb, Roche/Genentech, Exelixis, Eisai, Merck, Henguri, Immatics, AdaptImmune, Abivax. RKK—Consulting fees: Genentech/Roche, Gilead; Contracted research: Adaptimmune, Agios, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, EMD Serono, Exelixis, Merck, Novartis, Partner Therapeutic, QED, Taiho. RL—Consulting fees: AstraZeneca, Roche, Celsion, Guerbet. AL—Contracted research: Pfizer, Genentech (collaboration grants). IM—Consulting fees: Bristol-Myers Squibb, F-STAR, Alligator, Pharma Mar, AstraZeneca, Numab Therapeutics, Roche, Amunix, Gossamer, Molecular Partners, Merck-Serono, Genmab, PharmaMar; Contracted research: Roche, Bristol-Myers Squibb, Highlight Therapeutics, Alligator, Genmab, AstraZeneca. DJP—Consulting fees: ViiV Healthcare, Bayer, Hoffman La Roche, EISAI, H3B, MiNa Alpha Therapeutics, DaVolterra; Non-CME services: Hoffmann La Roche, EISAI; Contracted research: Merck Sharpe and Dohme, Bristol Myers Squibb (to institution). BS—Consulting fees: Adaptimmune, AstraZeneca, Bristol-Myers-Squibb, H3B Biomedicine, Ipsen, Lilly, Roche, Sirtex; Contracted research: Bristol-Myers Squibb, Sirtex Medical. AWW—Consulting fees: Eisai, Genentech; IP Rights: Cancer U; Salary: Blue Faery: The Adrienne Wilson Liver Cancer Association. TY—Consulting or advisory role: Bristol Myers-Squibb, MSD, Exelixis, Ipsen, Eisai, AstraZeneca, Bayer, Novartis, EMD Sereon, Abbvie, Pfizer, Ei Lilly, Sirtex, Sillajen, Taiho, OrigiMed, New B Innovation, Sirtex, H3 Biomedicine; Honoraria: Bristol Myers-Squibb, MSD, Exelixis, Ipsen, Eisai, AstraZeneca, Bayer, Novartis, EMD Sereon, Abbvie, Pfizer, Ei Lilly, Sirtex, Sillajen, Taiho, OrigiMed, New B Innovation, Sirtex, H3 Biomedicine. AZ—Consulting fees: Merck, Lilly, Eisai, Exelixis, Roche, Sanofi, Bayer. DMH, RIT—Nothing to disclose. SITC Staff: SMW—Shares owned: Pacific Biosciences of California Inc., Editas Medicine. EG, AK, LL—Nothing to disclose., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
6. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
- Author
-
Ziogas IA, Evangeliou AP, Giannis D, Hayat MH, Mylonas KS, Tohme S, Geller DA, Elias N, Goyal L, and Tsoulfas G
- Subjects
- Humans, Immunotherapy, Neoplasm Recurrence, Local, Nivolumab, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy
- Abstract
Background: Immune checkpoints inhibitors (ICIs) have emerged as a treatment option for several malignancies. Nivolumab, pembrolizumab, nivolumab plus ipilimumab, and atezolizumab plus bevacizumab have been approved for the management of advanced-stage hepatocellular carcinoma (HCC). We aimed to systematically review the literature and summarize the characteristics and outcomes of patients with HCC treated with ICIs., Methods: A systematic literature search of PubMed, the Cochrane Library, and ClinicalTrials.gov was performed according to the PRISMA statement (end of search date: November 7, 2020). Quality of evidence assessment was also performed., Results: Sixty-three articles including 2,402 patients were analyzed, 2,376 of whom received ICIs for unresectable HCC. Response to ICIs could be evaluated in 2,116 patients; the overall objective response rate (ORR) and disease control rate (DCR) were 22.7% and 60.7%, respectively, and the mean overall survival (OS) was 15.8 months. The ORR, DCR, and OS for nivolumab (n = 846) were 19.7%, 51.1%, and 18.7 months, respectively; for pembrolizumab (n = 435) they were 20.7%, 64.6% and 13.3 months, respectively. The combination of atezolizumab/bevacizumab (n = 460) demonstrated an ORR and DCR of 30% and 77%, respectively. The overall rate of treatment discontinuation because of adverse events was 14.9%. Fifteen patients received ICIs in the liver transplant (LT) setting (one pre-LT for bridging, 14 for post-LT recurrence); fatal graft rejection was reported in 40.0% (n = 6/15) and mortality in 80.0% (n = 12/15)., Conclusion: ICIs are safe and effective against unresectable HCC, but caution is warranted regarding their use in the LT setting because of the high graft rejection rate., Implications for Practice: This systematic review pooled the outcomes from studies reporting on the use of immune checkpoint inhibitors (ICIs) for the management of 2,402 patients with advanced-stage hepatocellular carcinoma (HCC), 2,376 of whom had unresectable HCC. The objective response rate and disease control rate were 22.7% and 60.7%, respectively, and the mean overall survival was 15.8 months. The overall rate of treatment discontinuation because of adverse events was 14.9%. Fifteen patients received ICIs in the liver transplant (LT) setting (one pre-LT for bridging, 14 for post-LT recurrence). Six of these patients experienced graft rejection (40.0%)., (© 2020 AlphaMed Press.)
- Published
- 2021
- Full Text
- View/download PDF
7. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
- Author
-
Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, Chahal P, Chang DT, Cloyd J, Covey AM, Glazer ES, Goyal L, Hawkins WG, Iyer R, Jacob R, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Sahai V, Schefter T, Singh G, Stein S, Vauthey JN, Venook AP, Yopp A, McMillian NR, Hochstetler C, and Darlow SD
- Subjects
- Humans, Sorafenib therapeutic use, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular therapy, Liver Neoplasms diagnosis, Liver Neoplasms therapy
- Abstract
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.
- Published
- 2021
- Full Text
- View/download PDF
8. Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma.
- Author
-
Goyal L, Chen CT, Pierce TT, and Deshpande V
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma secondary, Adult, Bile Duct Neoplasms diagnostic imaging, Bile Duct Neoplasms pathology, Chemotherapy, Adjuvant, Cholangiocarcinoma diagnostic imaging, Cholangiocarcinoma pathology, Fatal Outcome, Female, Hepatectomy, Humans, Liver Neoplasms diagnostic imaging, Liver Neoplasms surgery, Magnetic Resonance Imaging, Neoplasm Recurrence, Local, Tomography, X-Ray Computed, Bile Duct Neoplasms therapy, Cholangiocarcinoma therapy, Liver Neoplasms pathology, Pyrazoles therapeutic use, Pyrimidines therapeutic use, Pyrroles therapeutic use
- Published
- 2021
- Full Text
- View/download PDF
9. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
- Author
-
Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, and Duda DG
- Subjects
- Animals, Antineoplastic Combined Chemotherapy Protocols pharmacology, Carcinoma, Hepatocellular pathology, Cell Line, Tumor, Disease Models, Animal, Humans, Liver Neoplasms pathology, Mice, Phenylurea Compounds pharmacology, Pyridines pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, CD8-Positive T-Lymphocytes drug effects, Carcinoma, Hepatocellular drug therapy, Chemokine CXCL10 metabolism, Liver Neoplasms drug therapy, Phenylurea Compounds therapeutic use, Programmed Cell Death 1 Receptor antagonists & inhibitors, Pyridines therapeutic use
- Abstract
Background and Purpose: Combining inhibitors of vascular endothelial growth factor and the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but the disease-specific and agent-specific mechanisms of benefit remain unclear. We examined the efficacy and defined the mechanisms of benefit when combining regorafenib (a multikinase antivascular endothelial growth factor receptor inhibitor) with PD1 blockade in murine hepatocellular carcinoma (HCC) models., Basic Procedures: We used orthotopic models of HCC in mice with liver damage to test the effects of regorafenib-dosed orally at 5, 10 or 20 mg/kg daily-combined with anti-PD1 antibodies (10 mg/kg intraperitoneally thrice weekly). We evaluated the effects of therapy on tumor vasculature and immune microenvironment using immunofluorescence, flow cytometry, RNA-sequencing, ELISA and pharmacokinetic/pharmacodynamic studies in mice and in tissue and blood samples from patients with cancer., Main Findings: Regorafenib/anti-PD1 combination therapy increased survival compared with regofarenib or anti-PD1 alone in a regorafenib dose-dependent manner. Combination therapy increased regorafenib uptake into the tumor tissues by normalizing the HCC vasculature and increasing CD8 T-cell infiltration and activation at an intermediate regorafenib dose. The efficacy of regorafenib/anti-PD1 therapy was compromised in mice lacking functional T cells ( Rag1 -deficient mice). Regorafenib treatment increased the transcription and protein expression of CXCL10-a ligand for CXCR3 expressed on tumor-infiltrating lymphocytes-in murine HCC and in blood of patients with HCC. Using Cxcr3 -deficient mice, we demonstrate that CXCR3 mediated the increased intratumoral CD8 T-cell infiltration and the added survival benefit when regorafenib was combined with anti-PD1 therapy., Principal Conclusions: Judicious regorafenib/anti-PD1 combination therapy can inhibit tumor growth and increase survival by normalizing tumor vasculature and increasing intratumoral CXCR3+CD8 T-cell infiltration through elevated CXCL10 expression in HCC cells., Competing Interests: Competing interests: LG reports personal fees from Agios Pharmaceuticals, Alentis Therapeutics, QED Therapeutics, H3 Biomedicine, Taiho Pharmaceuticals, Debiopharm, Incyte Corporation, SIRTEX and AstraZeneca. AXZ is a consultant/advisory board member for Bayer. RKJ received honorarium from Amgen and consultant fees from Chugai, Ophthotech, Merck, SPARC, SynDevRx and XTuit. Dr Jain owns equity in XTuit, Enlight, SPARC, SynDevRx and Accurius Therapeutics and serves as a paid member of the boards of trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. He is a member of the scientific advisory board of Accurius Therapeutics. DZ, LF and the spouse of LLM are Bayer employees. MC is an AstraZeneca employee. DGD received consultant fees from Bayer, Simcere, Surface Oncology and Bristol Myers Squibb, and research grants from Bayer, Exelixis and Bristol Myers Squibb. No potential conflicts of interest were disclosed by other authors., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
10. Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons.
- Author
-
Bent EH, Wehrenberg-Klee E, Koay EJ, Goyal L, and Wo JY
- Subjects
- Combined Modality Therapy, Humans, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy
- Abstract
Treatment options in locally advanced hepatocellular carcinoma (HCC) have evolved considerably over the past few years with the recent approval of multiple systemic therapies and significant advances in locoregional therapy. Given the poor prognosis for patients with unresectable HCC, there is significant interest in rationally designed combination therapies. This article reviews the treatment options available to patients with locally advanced HCC and discusses the rationale, ongoing trials, and future prospects for combining locoregional and systemic therapy in both the definitive and neoadjuvant settings.
- Published
- 2020
- Full Text
- View/download PDF
11. Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus.
- Author
-
Bitterman DS, Edgington SK, Kilcoyne A, Kim DW, Eyler CE, Qadan M, Ferrone CR, Tanabe KK, Goyal L, Zhu AX, Wo JY, and Hong TS
- Subjects
- Aged, Aged, 80 and over, Humans, Male, Middle Aged, Carcinoma, Hepatocellular radiotherapy, Liver Neoplasms radiotherapy, Palliative Care methods, Thrombosis radiotherapy
- Published
- 2020
- Full Text
- View/download PDF
12. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.
- Author
-
Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyler C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, and Hong TS
- Subjects
- Aged, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Cause of Death, Disease Progression, Female, Follow-Up Studies, Humans, Incidence, Liver Failure mortality, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local, Photons adverse effects, Proportional Hazards Models, Proton Therapy adverse effects, Proton Therapy mortality, Retrospective Studies, Survival Analysis, Treatment Outcome, Carcinoma, Hepatocellular radiotherapy, Liver Failure epidemiology, Liver Neoplasms radiotherapy, Photons therapeutic use, Proton Therapy methods
- Abstract
Purpose: Ablative radiation therapy is increasingly being used for hepatocellular carcinoma (HCC) resulting in excellent local control rates; however, patients without evidence of disease progression often die from liver failure. The clinical benefit of proton- over photon-based radiation therapy is unclear. We therefore sought to compare clinical outcomes of proton versus photon ablative radiation therapy in patients with unresectable HCC., Methods and Materials: This is a single-institution retrospective study of patients treated during 2008 to 2017 with nonmetastatic, unresectable HCC not previously treated with liver-directed radiation therapy and who did not receive further liver-directed radiation therapy within 12 months after completion of index treatment. The primary outcome, overall survival (OS), was assessed using Cox regression. Secondary endpoints included incidence of non-classic radiation-induced liver disease (defined as increase in baseline Child-Pugh score by ≥2 points at 3 months posttreatment), assessed using logistic regression, and locoregional recurrence, assessed using Fine-Gray regression for competing risks. All outcomes were measured from radiation start date., Results: The median follow-up was 14 months. Of 133 patients with median age 68 years and 75% male, 49 (37%) were treated with proton radiation therapy. Proton radiation therapy was associated with improved OS (adjusted hazard ratio, 0.47; P = .008; 95% confidence interval [CI], 0.27-0.82). The median OS for proton and photon patients was 31 and 14 months, respectively, and the 24-month OS for proton and photon patients was 59.1% and 28.6%, respectively. Proton radiation therapy was also associated with a decreased risk of non-classic radiation-induced liver disease (odds ratio, 0.26; P = .03; 95% CI, 0.08-0.86). Development of nonclassic RILD at 3 months was associated with worse OS (adjusted hazard ratio, 3.83; P < .001; 95% CI, 2.12-6.92). There was no difference in locoregional recurrence, including local failure, between protons and photons., Conclusions: Proton radiation therapy was associated with improved survival, which may be driven by decreased incidence of posttreatment liver decompensation. Our findings support prospective investigations comparing proton versus photon ablative radiation therapy for HCC., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
13. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis.
- Author
-
Bitterman DS, Sanford NN, Niemierko A, Mahal BA, Qadan M, Ganguli S, Blaszkowsky LS, Zhu AX, Hong TS, Devlin PM, Goyal L, and Wo JY
- Subjects
- Aged, Brachytherapy, Carcinoma, Hepatocellular pathology, Databases, Factual, Dose Fractionation, Radiation, Female, Humans, Kaplan-Meier Estimate, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Propensity Score, Proportional Hazards Models, Retrospective Studies, Survival Rate, Carcinoma, Hepatocellular therapy, Embolization, Therapeutic methods, Liver Neoplasms therapy
- Abstract
Objectives: Most localized hepatocellular carcinoma (HCC) patients are not surgically operable or transplantation candidates, increasing the role for nonsurgical therapies. Ablative external beam radiotherapy (XRT) and transarterial radioembolization (TARE) are emerging radiotherapeutic treatments for localized HCC. We sought to evaluate their utilization and efficacy in a large nationwide cohort., Materials and Methods: We conducted an observational study of 2685 patients from the National Cancer Database (NCDB) diagnosed with American Joint Committee on Cancer 7th edition clinical stage I to III HCC between 2004 and 2015, treated with definitive-intent XRT delivered in 1 to 15 fractions or TARE. The association between treatment modality (XRT vs. TARE) and overall survival (OS) was defined using propensity score-weighted Kaplan-Meier estimators and propensity score-weighted multivariable Cox regressions., Results: Among 2685 patients, 2007 (74.7%) received TARE and 678 (25.3%) received XRT, with increasing usage for both from 2004 to 2015 (Ptrend<0.001), but with overall greater uptake and absolute usage of TARE. Patients who received TARE were more likely to have elevated alpha fetoprotein and more advanced stage (P<0.05 for all). Median OS was 14.5 months for the entire cohort. XRT was associated with an OS advantage compared with TARE on propensity score-unadjusted analysis (adjusted hazard ratio [AHR], 0.89; 95% confidence interval, 0.79-1.00; P=0.049), but not on propensity score-adjusted analysis (AHR, 0.99; 95% confidence interval, 0.86-1.13; P=0.829)., Conclusions: Our study demonstrates that while both XRT and TARE usage have increased with time, there was greater uptake and absolute use of TARE. We found no difference in survival between XRT and TARE after propensity score adjustment.
- Published
- 2019
- Full Text
- View/download PDF
14. Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China.
- Author
-
Goyal L, Qadan M, and Zhu AX
- Subjects
- China, Fluorouracil, Humans, Leucovorin, Oxaliplatin, Portal Vein, Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms
- Published
- 2019
- Full Text
- View/download PDF
15. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers.
- Author
-
Grieb BC, Goff LW, Goyal L, and Denlinger CS
- Subjects
- Animals, Biomarkers, Tumor, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular mortality, Clinical Trials as Topic, Combined Modality Therapy adverse effects, Combined Modality Therapy methods, Disease Management, Humans, Liver Neoplasms diagnosis, Liver Neoplasms etiology, Liver Neoplasms mortality, Molecular Targeted Therapy adverse effects, Molecular Targeted Therapy methods, Neoplasm Metastasis, Neoplasm Staging, Precision Medicine, Prognosis, Treatment Outcome, Carcinoma, Hepatocellular therapy, Liver Neoplasms therapy
- Abstract
The incidence and death rates of hepatocellular carcinoma (HCC) are rising. For more than a decade, the multikinase inhibitor sorafenib was the only U.S. Food and Drug Administration (FDA)-approved systemic therapy for HCC. However, since 2017, five additional agents have been approved in the first- or second-line setting. Although this represents an incredible victory for the field, there are no clear guidelines for agent selection on the basis of either patient or tumor characteristics. Here, we review the available systemic therapy options for advanced HCC and reported clinical data for each. We outline each agent's unique toxicity profile, potential impact on patient quality of life, monitoring recommendations, and supportive strategies. Last, we review molecular and immunologic classifications of HCC as well as preclinical data that may serve as a basis for future biomarker enriched clinical trials to enable precision oncology care in HCC.
- Published
- 2019
- Full Text
- View/download PDF
16. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
- Author
-
Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, and Zhu AX
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Biomarkers, Tumor blood, CD56 Antigen, Carcinoma, Hepatocellular blood, Carcinoma, Hepatocellular genetics, Carcinoma, Hepatocellular pathology, Cell Proliferation drug effects, Drug-Related Side Effects and Adverse Reactions classification, Drug-Related Side Effects and Adverse Reactions pathology, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Humans, Killer Cells, Natural drug effects, Leucovorin administration & dosage, Leucovorin adverse effects, Liver Neoplasms blood, Liver Neoplasms genetics, Liver Neoplasms pathology, Male, Middle Aged, Organoplatinum Compounds administration & dosage, Organoplatinum Compounds adverse effects, Placenta Growth Factor blood, Sorafenib adverse effects, T-Lymphocytes, Regulatory drug effects, Vascular Endothelial Growth Factor Receptor-1 blood, Vascular Endothelial Growth Factor Receptor-2 blood, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy, Sorafenib administration & dosage
- Abstract
Purpose: Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). The phase III SHARP trial showed a median time-to-progression (mTTP) of 5.5 months, overall response rate (ORR) of 2%, and median overall survival (mOS) of 10.7 months with sorafenib. FOLFOX4 has shown modest activity in advanced HCC. We evaluated the combination of sorafenib and modified (m)FOLFOX in a single-arm, multicenter phase II study., Patients and Methods: The study included Child-Pugh A patients with advanced HCC and no prior systemic therapies. Patients received sorafenib 400 mg twice a day for 2 weeks, followed by concurrent mFOLFOX [5-fluorouracil (5-FU) 1,200 mg/m
2 /day for 46 hours, leucovorin 200 mg/m2 , and oxaliplatin 85 mg/m2 biweekly]. The primary endpoint was mTTP with an alternative hypothesis of 7 months, and secondary endpoints included ORR, mOS, and circulating biomarkers., Results: The study enrolled 40 patients: HCV/EtOH/HBV, 43%/28%/13%; Child-Pugh A5, 70%. Notable grade 3/4 adverse events (AE) included AST/ALT elevation (28%/15%), diarrhea (13%), hyperbilirubinemia (10%), hand-foot syndrome (8%), and bleeding (8%). mTTP was 7.7 months [95% confidence interval (CI): 4.4-8.9], ORR 18%, and mOS 15.1 months (7.9-16.9). Sorafenib + mFOLFOX increased plasma PlGF, VEGF-D, sVEGFR1, IL12p70, and CAIX and CD4+ and CD8+ effector T lymphocytes and decreased plasma sVEGFR2 and s-c-KIT and regulatory T cells (Tregs). Shorter TTP was associated with high baseline sVEGFR1. Shorter TTP and OS were associated with increases in Tregs and CD56Dim natural killer (NK) cells after sorafenib alone and plasma sMET after combination treatment (all P < 0.05)., Conclusions: Sorafenib + mFOLFOX met the prespecified endpoint with encouraging efficacy but moderate hepatotoxicity. Thus, this regimen may be effective in select patients with adequate liver reserve. Biomarker evaluations suggested a correlation between time-to-progression (TTP) and angiogenic biomarkers and circulating Tregs., (©2018 American Association for Cancer Research.)- Published
- 2019
- Full Text
- View/download PDF
17. Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease.
- Author
-
Bhan I, Mosesso K, Goyal L, Philipp J, Kalinich M, Franses JW, Choz M, Oklu R, Toner M, Maheswaran S, Haber DA, Zhu AX, Chung RT, Aryee M, and Ting DT
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular blood, Chronic Disease, Female, Humans, Liver Diseases blood, Liver Neoplasms blood, Male, Middle Aged, Neoplastic Cells, Circulating, Carcinoma, Hepatocellular pathology, Epithelial Cells, Liquid Biopsy methods, Liver Diseases pathology, Liver Neoplasms pathology
- Published
- 2018
- Full Text
- View/download PDF
18. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis.
- Author
-
McDuff SGR, Remillard KA, Zheng H, Raldow AC, Wo JY, Eyler CE, Drapek LC, Goyal L, Blaszkowsky LS, Clark JW, Allen JN, Parikh AR, Ryan DP, Ferrone CR, Tanabe KK, Wolfgang JA, Zhu AX, and Hong TS
- Subjects
- Aged, Carcinoma, Hepatocellular pathology, Female, Follow-Up Studies, Humans, Liver Neoplasms secondary, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Prognosis, Radiotherapy Dosage, Radiotherapy, Intensity-Modulated methods, Retrospective Studies, Survival Rate, Carcinoma, Hepatocellular radiotherapy, Liver Neoplasms radiotherapy, Neoplasm Recurrence, Local radiotherapy, Radiotherapy Planning, Computer-Assisted methods, Re-Irradiation
- Abstract
Purpose: This study aimed to assess the safety and efficacy of administering liver reirradiation to patients with primary liver tumors or liver metastasis., Methods and Materials: A total of 49 patients (with 64 individual tumors) who received liver reirradiation at our institution between June 2008 and December 2016 were identified for retrospective review. Patients were treated to the same, different, or a combination of previously treated liver tumors for recurrent primary (53%) or metastatic (47%) disease using photons or protons. Clinical and treatment-related factors were compiled and patients were monitored for toxicity and evidence of classic or nonclassic radiation-induced liver disease. Survival was estimated with the Kaplan-Meier method and cumulative incidence of local failure (LF) was used to estimate LF using the Response Evaluation Criteria in Solid Tumors version 1.1., Results: The median age at the time of reirradiation was 72 years and the median interval between radiation courses was 9 months. At a median follow-up of 10.5 months, 36 patients (73%) had died, 9 patients (18%) were alive, and 4 patients (8%) were lost to follow-up. The median survival for the cohort was 14 months. The overall 1-year estimate of LF was 46.4%. The 1-year estimates of LF for liver metastases and hepatocellular carcinoma were 61.0% and 32.5%, respectively. The average prescription dose was similar between the reirradiation and initial courses (equivalent dose in 2 Gy fractions EQD2: 65.0 vs 64.3 Gy
α/β = 10 , respectively) but the average dose to the untreated liver was lower at the time of reirradiation (EQD2: 10.5 vs 13.9 Gyα/β = 3 , respectively, P = .01). Among patients with hepatocellular carcinoma, the average normal liver dose was significantly larger for patients who exhibited a worsening of Child-Pugh score after reirradiation compared with those who did not (1210 cGy vs 759 cGy, P = .04). With regard to toxicity, 85.7% of patients experienced grade 1 to 2 toxicity, 4.1% developed grade 3, and only 2 patients (4.1%) met the criteria for radiation-induced liver disease after reirradiation., Conclusions: Liver reirradiation may be an effective and safe option for select patients; however, further prospective study is necessary to establish treatment guidelines and recommended dosing., (Copyright © 2018. Published by Elsevier Inc.)- Published
- 2018
- Full Text
- View/download PDF
19. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
- Author
-
Wehrenberg-Klee E, Goyal L, Dugan M, Zhu AX, and Ganguli S
- Subjects
- Adult, Combined Modality Therapy, Hepatectomy, Humans, Immunotherapy, Male, Carcinoma, Hepatocellular radiotherapy, Embolization, Therapeutic methods, Liver Neoplasms radiotherapy, Nivolumab therapeutic use, Programmed Cell Death 1 Receptor antagonists & inhibitors, Radiofrequency Therapy methods, Yttrium Radioisotopes therapeutic use
- Abstract
Nivolumab has recently received approval by the Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Nivolumabs' overall response rate of 20% (El-Khoueiry et al. in Lancet 389:2492-2502, 2017) is a step forward for these patients, but there is significant room for improvement. We describe a case of combining Y-90 radioembolization with nivolumab for treatment of angioinvasive HCC, which successfully bridged patient to partial hepatectomy. Surgical pathology showed negative margins with complete pathological response. With the introduction of immunotherapy for HCC, combining Y-90 radioembolization with immunotherapy may enhance the anti-tumoral immune response of checkpoint inhibitors.
- Published
- 2018
- Full Text
- View/download PDF
20. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer.
- Author
-
Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, and Duda DG
- Subjects
- Adult, Aged, Aged, 80 and over, CD3 Complex metabolism, CD4-Positive T-Lymphocytes cytology, CD8-Positive T-Lymphocytes cytology, Carcinoma, Hepatocellular blood, Cholangiocarcinoma blood, Female, Follow-Up Studies, Humans, Interleukin-2 Receptor alpha Subunit metabolism, Interleukin-7 Receptor alpha Subunit metabolism, Killer Cells, Natural cytology, Lymphocyte Subsets, Male, Middle Aged, Proton Therapy, T-Lymphocytes metabolism, Time Factors, Treatment Outcome, Carcinoma, Hepatocellular radiotherapy, Cholangiocarcinoma radiotherapy, Immunotherapy methods, Liver Neoplasms blood, Liver Neoplasms radiotherapy, T-Lymphocytes cytology
- Abstract
Purpose: Irradiation may have significant immunomodulatory effects that impact tumor response and could potentiate immunotherapeutic approaches. The purposes of this study were to prospectively investigate circulating lymphoid cell population fractions during hypofractionated proton therapy (HPT) in blood samples of liver cancer patients and to explore their association with survival., Methods and Materials: We collected serial blood samples before treatment and at days 8 and 15 of HPT from 43 patients with liver cancer-22 with hepatocellular carcinoma (HCC) and 21 with intrahepatic cholangiocarcinoma (ICC)-enrolled in a phase 2 clinical trial. All patients received 15 fractions of proton therapy to a median dose of 58 Gy (relative biological effectiveness). We used flow cytometry to measure the changes in the fractions of total CD3
+ , CD4+ , and CD8+ T cells; CD4+ CD25+ T cells; CD4+ CD127+ T cells; CD3+ CD8+ CD25+ activated cytotoxic T lymphocytes (CTLs); and CD3- CD56+ natural killer cells., Results: With a median follow-up period of 42 months, median overall survival (OS) in the study cohort was 30.6 months for HCC and 14.5 months for ICC patients. Longer OS was significantly correlated with greater CD4+ CD25+ T-cell (P = .003) and CD4+ CD127+ T-cell (P = .01) fractions at baseline only in ICC patients. In HCC patients, the fraction of activated CTLs mid treatment (at day 8) was significantly associated with OS (P = .007). These findings suggest a differential relevance of immunomodulation by HPT in these liver cancers., Conclusions: Antitumor immunity may depend on maintenance of a sufficiently high number of activated CTLs during HPT in HCC patients and CD4+ CD25+ T cells and CD4+ CD127+ T cells prior to treatment in ICC patients. These results could guide the design of future studies to determine the optimal treatment schedules when combining irradiation with specific immunotherapy approaches., (Copyright © 2018 Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
21. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.
- Author
-
Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, and Zhu AX
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Disease Progression, Dose Fractionation, Radiation, Female, Follow-Up Studies, Genotype, Humans, Liver Neoplasms diagnosis, Liver Neoplasms genetics, Male, Middle Aged, Mutation, Prognosis, Radiation Dosage, Treatment Failure, Treatment Outcome, Tumor Burden, Liver Neoplasms radiotherapy, Liver Neoplasms secondary, Proton Therapy adverse effects, Proton Therapy methods, Radiosurgery adverse effects, Radiosurgery methods
- Abstract
Background: We evaluated the efficacy and safety of risk-adapted, proton-based stereotactic body radiation therapy (SBRT) for liver metastases from solid tumors., Methods: This single-arm phase II single institutional study (NCT01239381) included patients with limited extrahepatic disease, 800 mL or greater of uninvolved liver, and no cirrhosis or Child-Pugh A, who had received proton-based SBRT to one to four liver metastases from solid tumors. Treatment comprised 30 to 50 Gray equivalent (GyE) in five fractions based on the effective volume of liver irradiated. Sample size was calculated to determine if local control (LC) at one year was greater than 70%. The cumulative incidence of local failure was used to estimate LC. The association of tumor characteristics, including genetic alterations in common cancer genes such as BRAF, EGFR, HER2, KRAS, NRAS, PIK3CA, and TP53 with local tumor control, was assessed. All statistical tests were two-sided., Results: Eighty-nine patients were evaluable (colorectal, n = 34; pancreatic, n = 13; esophagogastric, n = 12; other, n = 30). Median tumor size was 2.5 cm (range = 0.5-11.9 cm). Median dose was 40 GyE (range = 30-50 GyE), and median follow-up was 30.1 months (range = 14.7-53.8 months). There was no grade 3 to 5 toxicity. Median survival time was 18.1 months. The one- and three-year LC rates were 71.9% (95% confidence limit [CL] = 62.3% to 80.9%) and 61.2% (95% CL = 50.8% to 71.8%), respectively. For large tumors (≥6 cm), one-year LC remained high at 73.9% (95% CL = 54.6% to 89.8%). Mutation in the KRAS oncogene was the strongest predictor of poor LC (P = .02). Tumor with both mutant KRAS and TP53 were particularly radioresistant, with a one-year LC rate of only 20.0%, compared with 69.2% for all others (P = .001)., Conclusions: We report the largest prospective evaluation to date of liver SBRT for hepatic metastases, and the first with protons. Protons were remarkably well tolerated and effective even for metastases that were 6 cm or larger. KRAS mutation is a strong predictor of poor LC, stressing the need for tumor genotyping prior to SBRT and treatment intensification in this patient subset., (© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
22. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.
- Author
-
Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, Weitz DA, Sequist LV, Ryan DP, Chung RT, Zhu AX, Isselbacher KJ, Ting DT, Toner M, Maheswaran S, and Haber DA
- Subjects
- Carcinoma, Hepatocellular blood, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular therapy, Cell Lineage, Cell Separation instrumentation, Hep G2 Cells, Hepatitis B, Chronic blood, High-Throughput Nucleotide Sequencing instrumentation, High-Throughput Nucleotide Sequencing methods, Humans, Lab-On-A-Chip Devices, Liver Cirrhosis blood, Liver Neoplasms blood, Liver Neoplasms pathology, Liver Neoplasms therapy, Logistic Models, Precancerous Conditions blood, Predictive Value of Tests, Sequence Analysis, RNA instrumentation, Sequence Analysis, RNA methods, Single-Cell Analysis, Biomarkers, Tumor blood, Carcinoma, Hepatocellular diagnosis, Cell Separation methods, Early Detection of Cancer methods, High-Throughput Screening Assays, Liver Neoplasms diagnosis, Neoplastic Cells, Circulating, RNA, Messenger blood, RNA, Neoplasm blood, Transcriptome
- Abstract
Circulating tumor cells (CTCs) are shed into the bloodstream by invasive cancers, but the difficulty inherent in identifying these rare cells by microscopy has precluded their routine use in monitoring or screening for cancer. We recently described a high-throughput microfluidic CTC-iChip, which efficiently depletes hematopoietic cells from blood specimens and enriches for CTCs with well-preserved RNA. Application of RNA-based digital PCR to detect CTC-derived signatures may thus enable highly accurate tissue lineage-based cancer detection in blood specimens. As proof of principle, we examined hepatocellular carcinoma (HCC), a cancer that is derived from liver cells bearing a unique gene expression profile. After identifying a digital signature of 10 liver-specific transcripts, we used a cross-validated logistic regression model to identify the presence of HCC-derived CTCs in nine of 16 (56%) untreated patients with HCC versus one of 31 (3%) patients with nonmalignant liver disease at risk for developing HCC (P < 0.0001). Positive CTC scores declined in treated patients: Nine of 32 (28%) patients receiving therapy and only one of 15 (7%) patients who had undergone curative-intent ablation, surgery, or liver transplantation were positive. RNA-based digital CTC scoring was not correlated with the standard HCC serum protein marker alpha fetoprotein (P = 0.57). Modeling the sequential use of these two orthogonal markers for liver cancer screening in patients with high-risk cirrhosis generates positive and negative predictive values of 80% and 86%, respectively. Thus, digital RNA quantitation constitutes a sensitive and specific CTC readout, enabling high-throughput clinical applications, such as noninvasive screening for HCC in populations where viral hepatitis and cirrhosis are prevalent., Competing Interests: The authors declare no conflict of interest.
- Published
- 2017
- Full Text
- View/download PDF
23. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
- Author
-
Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, and Zhu AX
- Subjects
- Adult, Aged, Aged, 80 and over, Bile Duct Neoplasms mortality, Bile Duct Neoplasms pathology, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Cholangiocarcinoma mortality, Cholangiocarcinoma pathology, Female, Follow-Up Studies, Humans, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Prognosis, Prospective Studies, Radiation Dose Hypofractionation, Survival Rate, Bile Duct Neoplasms radiotherapy, Carcinoma, Hepatocellular radiotherapy, Cholangiocarcinoma radiotherapy, Liver Neoplasms radiotherapy, Proton Therapy
- Abstract
Purpose: To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)., Materials and Methods: In this single-arm, phase II, multi-institutional study, 92 patients with biopsy-confirmed HCC or ICC, determined to be unresectable by multidisciplinary review, with a Child-Turcotte-Pugh score (CTP) of A or B, ECOG performance status of 0 to 2, no extrahepatic disease, and no prior radiation received 15 fractions of proton therapy to a maximum total dose of 67.5 Gy equivalent. Sample size was calculated to demonstrate > 80% local control (LC) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria at 2 years for HCC patients, with the parallel goal of obtaining acceptable precision for estimating outcomes for ICC., Results: Eighty-three patients were evaluable: 44 with HCC, 37 with ICC, and two with mixed HCC/ICC. The CTP score was A for 79.5% of patients and B for 15.7%; 4.8% of patients had no cirrhosis. Prior treatment had been given to 31.8% of HCC patients and 61.5% of ICC patients. The median maximum dimension was 5.0 cm (range, 1.9 to 12.0 cm) for HCC patients and 6.0 cm (range, 2.2 to 10.9 cm) for ICC patients. Multiple tumors were present in 27.3% of HCC patients and in 12.8% of ICC patients. Tumor vascular thrombosis was present in 29.5% of HCC patients and in 28.2% of ICC patients. The median dose delivered to both HCC and ICC patients was 58.0 Gy. With a median follow-up among survivors of 19.5 months, the LC rate at 2 years was 94.8% for HCC and 94.1% for ICC. The overall survival rate at 2 years was 63.2% for HCC and 46.5% ICC., Conclusion: High-dose hypofractionated proton therapy demonstrated high LC rates for HCC and ICC safely, supporting ongoing phase III trials of radiation in HCC and ICC., Competing Interests: Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article., (© 2015 by American Society of Clinical Oncology.)
- Published
- 2016
- Full Text
- View/download PDF
24. The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.
- Author
-
Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesey N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, and Deshpande V
- Subjects
- Adenocarcinoma diagnosis, Adenocarcinoma genetics, Aged, Bile Duct Neoplasms genetics, Carcinoma, Hepatocellular genetics, Cholangiocarcinoma genetics, Female, Follow-Up Studies, Humans, Liver Neoplasms genetics, Male, Neoplasm Grading, Prognosis, RNA, Messenger genetics, Albumins genetics, Bile Duct Neoplasms diagnosis, Carcinoma, Hepatocellular diagnosis, Cholangiocarcinoma diagnosis, DNA genetics, In Situ Hybridization methods, Liver Neoplasms diagnosis
- Abstract
Background: Intrahepatic cholangiocarcinoma (ICC) often is a diagnosis determined by exclusion. Distinguishing ICC from other metastatic adenocarcinomas based on histopathologic or immunohistochemical analysis often is difficult and requires an extensive workup. This study aimed to determine whether albumin, whose expression is restricted to the liver, has potential as a biomarker for ICC using a novel and highly sensitive RNA in situ hybridization (ISH) platform., Methods: Modified branched DNA probes were developed for albumin RNA ISH. The study evaluated 467 patient samples of primary and metastatic lesions., Results: Of the 467 samples evaluated, 83 were ICCs, 42 were hepatocellular carcinomas (HCCs), and 332 were nonhepatic carcinomas including tumors arising from the perihilar region and bile duct, pancreas, stomach, esophagus, colon, breast, ovary, endometrium, kidney, and urinary bladder. Albumin RNA ISH was highly sensitive for cancers of liver origin, staining positive in 82 (99 %) of 83 ICCs and in 42 HCCs (100 %). Perihilar and distal bile duct carcinomas as well as carcinomas arising at other sites tested negative for albumin. Notably, 6 (22 %) of 27 intrahepatic tumors previously diagnosed as carcinomas of undetermined origin tested positive for albumin., Conclusions: Albumin RNA ISH is a sensitive and highly specific diagnostic tool for distinguishing ICC from metastatic adenocarcinoma to the liver or carcinoma of unknown origin. Albumin RNA ISH could replace the extensive diagnostic workup, leading to timely confirmation of the ICC diagnosis. Additionally, the assay could serve as a guide to distinguish ICC from perihilar adenocarcinoma.
- Published
- 2016
- Full Text
- View/download PDF
25. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
- Author
-
Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, and Ganguli S
- Subjects
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Ethiodized Oil administration & dosage, Female, Hemostatics administration & dosage, Humans, Male, Microspheres, Middle Aged, Particle Size, Retrospective Studies, Treatment Outcome, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Carcinoma, Hepatocellular therapy, Chemoembolization, Therapeutic methods, Delayed-Action Preparations administration & dosage, Liver Neoplasms therapy
- Abstract
Purpose: To compare the safety and efficacy of using 70-150 μm drug-eluting beads (DEBs) (LC BeadM1; Biocompatibles UK Ltd, Farnham, Surrey, United Kingdom) in addition to 100-300 μm DEBs with 100-300 μm DEBs alone in transarterial chemoembolization for treatment of hepatocellular carcinoma (HCC)., Materials and Methods: A cohort of patients with HCC who underwent transarterial chemoembolization with two vials of 100-300 μm DEBs (group 1, 55 procedures among 42 patients, 33 men, average Model for End-Stage Liver Disease score 10 ± 0.6, 67% Child-Pugh A, 33% Child-Pugh B) was retrospectively compared with a cohort of patients who underwent transarterial chemoembolization with one vial of 70-150 μm DEBs followed by one vial of 100-300 μm DEBs (group 2, 51 procedures among 42 patients, 29 men, average Model for End-Stage Liver Disease score 9 ± 0.6, 73% Child-Pugh A, 27% Child-Pugh B) in regard to adverse events and response on 1-month follow-up imaging using modified Response Evaluation Criteria In Solid Tumors criteria., Results: There was no difference in 1-month imaging response (P = .3). Patients in group 2 were readmitted more often within 1 month for hepatobiliary adverse events (group 2, 25%; group 1, 9%; P < .0001), including ascites, gastrointestinal hemorrhage, biliary dilatation, and cholecystitis., Conclusions: Despite similar efficacy based on short-term follow-up imaging, transarterial chemoembolization with smaller DEBs (70-150 μm) followed by larger DEBs (100-300 μm) may cause more hepatobiliary adverse events., (Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
26. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
- Author
-
Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J, and Zhu AX
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular metabolism, Female, Humans, Liver metabolism, Liver Diseases metabolism, Liver Neoplasms metabolism, Male, Middle Aged, Treatment Outcome, Triazoles adverse effects, Triazoles blood, Triazoles pharmacokinetics, Carcinoma, Hepatocellular drug therapy, HSP90 Heat-Shock Proteins antagonists & inhibitors, Liver Neoplasms drug therapy, Triazoles therapeutic use
- Abstract
Background: Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90 client proteins involved in hepatocarcinogenesis, thereby making it an attractive therapy for HCC. This Phase I study was performed to establish the safety, tolerability, recommended Phase 2 dose (RP2D), and preliminary clinical activity of ganetespib in previously treated patients with advanced HCC., Methods: Patients with advanced HCC, Child-Pugh A cirrhosis, progression on or intolerance to sorafenib, and ECOG PS ≤ 1 were enrolled in a standard 3x3 dose escalation study at doses of 100 mg/m(2), 150 mg/m(2), and 200 mg/m(2) IV given on days 1, 8, and 15 of each 28-day cycle. Objective response by RECIST version 1.1 criteria was evaluated by CT/MRI every 8 weeks., Results: Fourteen patients were enrolled in this trial and received at least one dose of the study drug. Of the 14 patients: median age, 57 years old; male 71 %; Asian 36 %; HCC etiology (HBV 36 %, HCV 43 %, Hemachromatosis 7 %, unknown 21 %); Child Pugh Class (A 93 %, B 7 %); median number of prior treatments 2; median baseline AFP 70.1 ng/mL. The RP2D was determined to be 200 mg/m(2). The most commonly seen AEs were diarrhea (93 %), fatigue (71 %), AST elevation (64 %), and hyperglycemia (64 %). The most common Gr 3/4 AEs were hyperglycemia (21 %) and lipasemia (21 %). One (7 %) patient had a fatal AE, septic shock, within 30 days of receiving the study drug. One dose-limiting toxicity, grade 3 lipasemia, was observed at the 100 mg/m(2) dose. Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m(2)), 0.76 h, and 191 L (100.4 L/m(2)), respectively. No objective responses were seen; one patient (7 %) had stable disease at 16 weeks. Median time to progression was 1.8 months, and median overall survival was 7.2 months., Conclusion: Ganetespib had a manageable safety profile in patients with advanced HCC who had progressed on at least one line of systemic therapy. The pharmacokinetic profile showed that ganetespib exposure in patients with mild hepatic dysfunction is similar to that seen in patients with normal liver function. Ganetespib showed limited clinical benefit in patients with advanced HCC in this phase I trial.
- Published
- 2015
- Full Text
- View/download PDF
27. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
- Author
-
Hato T, Goyal L, Greten TF, Duda DG, and Zhu AX
- Subjects
- CTLA-4 Antigen antagonists & inhibitors, CTLA-4 Antigen metabolism, Carcinoma, Hepatocellular immunology, Clinical Trials as Topic, Humans, Liver Neoplasms immunology, Programmed Cell Death 1 Receptor antagonists & inhibitors, Programmed Cell Death 1 Receptor metabolism, Carcinoma, Hepatocellular therapy, Immunotherapy, Liver Neoplasms therapy
- Abstract
Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives., (© 2014 by the American Association for the Study of Liver Diseases.)
- Published
- 2014
- Full Text
- View/download PDF
28. Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.
- Author
-
Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, and Zhu AX
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacokinetics, Carcinoma, Hepatocellular pathology, Female, Humans, Infusions, Intravenous, Karnofsky Performance Status, Liver Function Tests, Liver Neoplasms pathology, Male, Maximum Tolerated Dose, Middle Aged, Severity of Illness Index, Spermine adverse effects, Spermine pharmacokinetics, Spermine therapeutic use, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy, Spermine analogs & derivatives
- Abstract
Purpose: N(1),N(11)-diethylnorspermine (DENSPM), a synthetic analog of the naturally occurring polyamine spermine, can induce polyamine depletion and inhibit tumor cell growth. The objectives of this phase I study were to assess the safety, maximum-tolerated dose (MTD), pharmacokinetics, and preliminary antitumor activity of DENSPM in advanced HCC., Methods: Patients with measurable advanced HCC, Child-Pugh A or B cirrhosis, CLIP score ≤3, and Karnofsky score ≥60 % were eligible. DENSPM was given as a short intravenous infusion on days 1, 3, 5, 8, 10, and 12 of each 28-day cycle. The starting dose of 30 mg/m(2) was escalated at a fixed increment of 15 mg/m(2) until the MTD was identified. The plasma pharmacokinetics of DENSPM for the first and last doses given in cycle 1 was characterized., Results: Thirty-eight patients (male 79 %; median age 61 years; Child-Pugh A 84 %; ≥1 prior systemic therapy 45 %) were enrolled and treated. The most common adverse events (AEs) ≥grade 1 were fatigue (53 %), nausea (34 %), diarrhea (32 %), vomiting (32 %), anemia (29 %), and elevated AST (29 %). The most common grade 3-4 AEs were fatigue/asthenia (13 %), elevated AST (13 %), hyperbilirubinemia (11 %), renal failure (8 %), and hyperglycemia (8 %). The MTD was 75 mg/m(2). There were no objective responses, although 7/38 (18 %) patients achieved stable disease for ≥16 weeks. The overall mean (±SD) total body clearance for the initial dose, 66.3 ± 35.9 L/h/m(2) (n = 16), was comparable to the clearance in patients with normal to near normal hepatic function. Drug levels in plasma decayed rapidly immediately after the infusion but remained above 10 nM for several days after dosing at the MTD., Conclusions: N(1),N(11)-diethylnorspermine treatment at the MTD of 75 mg/m(2), given intravenously every other weekday for two consecutive weeks of each 28-day cycle, was relatively well tolerated in patients with advanced HCC including those with mild-to-moderate liver dysfunction. This administration schedule provided prolonged systemic exposure to potentially effective concentrations of the drug. Stable disease was seen in 18 % of patients receiving DENSPM treatment. Further evaluation of DENSPM monotherapy for advanced HCC does not appear to be justified because of insufficient evidence of clinical benefit in the patients evaluated in this study.
- Published
- 2013
- Full Text
- View/download PDF
29. Targeting the HGF/c-MET pathway in hepatocellular carcinoma.
- Author
-
Goyal L, Muzumdar MD, and Zhu AX
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Carcinoma, Hepatocellular metabolism, Clinical Trials as Topic, Humans, Liver Neoplasms metabolism, Molecular Targeted Therapy, Proto-Oncogene Proteins c-met metabolism, Signal Transduction, Antineoplastic Agents pharmacology, Carcinoma, Hepatocellular drug therapy, Hepatocyte Growth Factor physiology, Liver Neoplasms drug therapy, Proto-Oncogene Proteins c-met antagonists & inhibitors
- Abstract
Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and mortality worldwide. Despite improvements in local therapies, including surgical resection, liver transplantation, and transarterial embolization, the prognosis remains poor for the majority of patients who develop recurrence or present with advanced disease. Systemic therapy with the tyrosine kinase inhibitor sorafenib represents a milestone in advanced HCC but provides a limited survival benefit. Ongoing efforts to study hepatocarcinogenesis have identified an important role for c-MET signaling in the promotion of tumor growth, angiogenesis, and metastasis. In this review, we summarize the preclinical data from human tissue, cell lines, and animal models that implicate c-MET in the pathogenesis of HCC. We also evaluate potential biomarkers that may estimate prognosis or predict response to c-MET inhibitors for more rational clinical trial design. Finally, we discuss the latest clinical trials of c-MET inhibitors in advanced HCC., (©2013 AACR.)
- Published
- 2013
- Full Text
- View/download PDF
30. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
- Author
-
Aiwu Ruth He, Robin Kate Kelley, Ahmed Kaseb, David J. Pinato, Lipika Goyal, Amaia Lujambio, Bruno Sangro, Peter R. Galle, Ignacio Melero, Ghassan K. Abou-Alfa, Austin G. Duffy, Roberto I. Troisi, Riccardo Lencioni, Andrew X. Zhu, Anthony B. El-Khoueiry, Ann-Lii Cheng, Tim F. Greten, Richard S. Finn, Donna Mabry Hrones, Andrea Wilson Woods, Thomas Yau, Greten, T. F., Abou-Alfa, G. K., Cheng, A. -L., Duffy, A. G., El-Khoueiry, A. B., Finn, R. S., Galle, P. R., Goyal, L., He, A. R., Kaseb, A. O., Kelley, R. K., Lencioni, R., Lujambio, A., Mabry Hrones, D., Pinato, D. J., Sangro, B., Troisi, R., Wilson Woods, A., Yau, T., Zhu, A. X., and Melero, I.
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,antineoplastic protocols ,guidelines as topic ,immunotherapy ,liver neoplasms ,Bevacizumab ,medicine.medical_treatment ,Immunology ,Guidelines as Topic ,Disease ,Quality of life (healthcare) ,Atezolizumab ,Internal medicine ,liver neoplasm ,medicine ,Immunology and Allergy ,Humans ,Radiation treatment planning ,RC254-282 ,Pharmacology ,business.industry ,Liver Neoplasms ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Guideline ,Immunotherapy ,medicine.disease ,antineoplastic protocol ,Molecular Medicine ,business ,Human ,medicine.drug - Abstract
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunotherapy has demonstrated safety and efficacy in later lines of therapy as well, and ongoing trials are investigating novel combinations of ICIs and TKIs, in addition to interventions earlier in the course of disease or in combination with liver-directed therapies. Because HCC usually develops against a background of cirrhosis, immunotherapy for liver tumors is complex and oncologists need to account for both immunological and hepatological considerations when developing a treatment plan for their patients. To provide guidance to the oncology community on important concerns for the immunotherapeutic care of HCC, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for HCC, including diagnosis and staging, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with HCC.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.